BJH - 2018, issue Abstract Book BHS, february 2018
A. Betsch , O. Rutgeerts , S. Fevery MD, PhD, B. Sprangers MD, PhD, D. Dierickx MD, PhD, M. Beckers MD, PhD
BJH - 2018, issue Abstract Book BHS, february 2018
J. Van Ham , M. Delforge MD, PhD, A. Janssens MD, PhD, J. Raddoux , M. Beckers MD, PhD, T. Devos MD, PhD, D. Dierickx MD, PhD, V. Vergote MD, J. Maertens MD, PhD, H. Schoemans MD, PhD, P. Vandenberghe MD, PhD
BJH - volume 7, issue 6, december 2016
M. Beckers MD, PhD, D. Dierickx MD, PhD, T. Devos MD, PhD, S. Fevery MD, PhD, B. Sprangers MD, PhD
One of the hallmarks of failure of elimination of malignant cells by activated T-cells is the immunosuppressive environment of the tumour. Myeloid-derived suppressor cells contribute to this immunosuppressive environment by inhibition of the adaptive and innate immune system. In this article we describe the current knowledge of the role of myeloid-derived suppressor cells in the progression of haematological malignancies.
(BELG J HEMATOL 2016;7(6):213–6)
Read moreBJH - volume 7, issue 3, june 2016
L. Barrios MD, M. Beckers MD, PhD, G. Verhoef MD, PhD, D. Dierickx MD, PhD
Primary central nervous system lymphoma is a rare lymphoproliferative disorder confined to the central nervous system. Here we report a case of a 73-year-old female with an intracerebral lymphoma, discussing clinical presentation, diagnosis and treatment. Primary central nervous system lymphoma is a subtype of non-Hodgkin lymphoma which, in more than 90% of the cases, are diffuse large B-cell lymphomas. Clinical presentation is broad; the most common presentation in an immunocompetent patient is a focal neurological deficit. The neuroimaging technique of choice for diagnosis is contrast enhanced magnetic resonance. Histopathologic diagnosis is essential, which is mostly performed by a stereotactic guided biopsy. The backbone of treatment for primary central nervous system lymphoma is high-dose methotrexate, which can be combined with other chemotherapy, whole brain radiotherapy, corticosteroids and rituximab.
(BELG J HEMATOL 2016; 7(3):118–22)
Read more
Top
